Dyadic to Showcase at Investor Conferences and BPI East
Company Overview: Dyadic International, Inc. is a biotechnology company focused on producing high-value proteins for life sciences, food, and industrial applications using proprietary gene expression platforms.
Upcoming Conferences: Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East, to engage with investors and industry partners.
Trade with 70% Backtested Accuracy
Analyst Views on DYAI
About DYAI
About the author
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Dyadic to Showcase at Investor Conferences and BPI East
Company Overview: Dyadic International, Inc. is a biotechnology company focused on producing high-value proteins for life sciences, food, and industrial applications using proprietary gene expression platforms.
Upcoming Conferences: Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East, to engage with investors and industry partners.
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Conference Call Overview: Dyadic International held its Q2 2025 earnings conference call on August 13, 2025, featuring key participants including President Joe Hazelton and CFO Ping Wang Rawson, who provided insights into the company's financial results and strategic direction.
Forward-Looking Statements: The call included forward-looking statements that carry risks and uncertainties, with a disclaimer from Dyadic regarding their obligation to update these projections.
Dyadic International Narrows Q2 Loss
Earnings Report and Strategic Shift: Dyadic International reported Q2 2025 earnings with a GAAP revenue of $967,000, marking a year-over-year increase. The company has undergone a rebranding to Dyadic Applied Biosolutions and shifted its focus from research to commercializing engineered protein platforms in life sciences and bioindustrial markets.
Financial Outlook and Cost Management: The company narrowed its net loss to $1.79 million while managing general and administrative costs effectively. Management anticipates additional revenues from product launches by late 2025 and aims to maintain operating expenses at or below prior-year levels.
Dyadic (DYAI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Dyadic anticipates $500,000 milestone and targets commercialization ramp through 2026
Company Transformation: Dyadic International has transitioned from a research-focused entity to a commercially-driven biotechnology firm, rebranding as Dyadic Applied BioSolutions and emphasizing its capabilities in scalable, animal-free protein production for various applications. The company aims to achieve cash flow positivity by the end of 2026.
Financial Performance: In Q2 2025, Dyadic reported a significant revenue increase to $967,000, alongside reduced operational losses, while successfully raising $5.3 million through equity offerings to support product development and commercialization efforts across life sciences and food nutrition sectors.
HC Wainwright & Co. Initiates Coverage on Dyadic International with a Buy Rating and Sets Price Target at $3
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Dyadic to Showcase at Investor Conferences and BPI East
Company Overview: Dyadic International, Inc. is a biotechnology company focused on producing high-value proteins for life sciences, food, and industrial applications using proprietary gene expression platforms.
Upcoming Conferences: Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including the H.C. Wainwright 27th Annual Global Investment Conference and BioProcess International BPI East, to engage with investors and industry partners.
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Conference Call Overview: Dyadic International held its Q2 2025 earnings conference call on August 13, 2025, featuring key participants including President Joe Hazelton and CFO Ping Wang Rawson, who provided insights into the company's financial results and strategic direction.
Forward-Looking Statements: The call included forward-looking statements that carry risks and uncertainties, with a disclaimer from Dyadic regarding their obligation to update these projections.
Dyadic International Narrows Q2 Loss
Earnings Report and Strategic Shift: Dyadic International reported Q2 2025 earnings with a GAAP revenue of $967,000, marking a year-over-year increase. The company has undergone a rebranding to Dyadic Applied Biosolutions and shifted its focus from research to commercializing engineered protein platforms in life sciences and bioindustrial markets.
Financial Outlook and Cost Management: The company narrowed its net loss to $1.79 million while managing general and administrative costs effectively. Management anticipates additional revenues from product launches by late 2025 and aims to maintain operating expenses at or below prior-year levels.
Dyadic (DYAI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Dyadic anticipates $500,000 milestone and targets commercialization ramp through 2026
Company Transformation: Dyadic International has transitioned from a research-focused entity to a commercially-driven biotechnology firm, rebranding as Dyadic Applied BioSolutions and emphasizing its capabilities in scalable, animal-free protein production for various applications. The company aims to achieve cash flow positivity by the end of 2026.
Financial Performance: In Q2 2025, Dyadic reported a significant revenue increase to $967,000, alongside reduced operational losses, while successfully raising $5.3 million through equity offerings to support product development and commercialization efforts across life sciences and food nutrition sectors.
